Here’s the latest overview based on available up-to-date sources.
- MAHA refers to a group of disorders causing intravascular red cell fragmentation, with conditions like TTP/HUS and other thrombotic microangiopathies. Recent reviews emphasize its broad etiologies, including autoimmune, infectious, malignant, and iatrogenic causes, and highlight the importance of prompt diagnostic workup and targeted therapy.[1][4]
- Key diagnostic hallmarks include schistocytes on the blood smear, elevated LDH, reduced haptoglobin, thrombocytopenia, and evidence of organ involvement (kidney, CNS) in many TMAs. Therapies vary by cause but often involve plasma exchange for classic TTP and disease-specific strategies for atypical HUS or secondary MAHA.[6][7][1]
- In cancer-associated MAHA and other secondary MAHAs, treatment focuses on the underlying malignancy; plasmapheresis may be less beneficial, and prognosis tends to be more dependent on cancer control and performance status.[3][9]
- Recent reviews and case reports underscore evolving approaches, including complement-directed therapies for complement-mediated MAHAs and the need to distinguish MAHA from other anemia etiologies (e.g., megaloblastic anemia or DIC) to avoid unnecessary plasma exchange.[5][7][10]
Illustration: A typical diagnostic pathway
- Suspect MAHA with anemia and thrombocytopenia; check blood smear for schistocytes.
- Order LDH, haptoglobin, bilirubin, reticulocyte count, and coagulation studies to differentiate microangiopathies from DIC or immune hemolysis.
- Initiate urgent management based on likely cause: plasma exchange for suspected TTP; treat underlying disease in secondary MAHA; consider complement inhibitors if complement-mediated MAHA is suspected.
- Monitor organ function (renal, neurologic) and adjust therapy as test results clarify the diagnosis.
If you’d like, I can pull the most recent primary sources or craft a succinct, cited brief for Montréal-based clinical teams, and I can also summarize how MAHA presents differently in cancer-related cases versus autoimmune TTP.
Sources
Red blood cells (RBCs) start to break down early in hemolytic anemia, which can be chronic or life-threatening. It should be considered while determining if normocytic or macrocytic anemia is present. Hemolysis in the reticuloendothelial system may happen intravascularly, extravascularly, or both. It accounts for a broad spectrum of laboratory and clinical situations, both physiological and pathological. Whenever the frequency of RBC breakdown is rapid enough to lower hemoglobin levels below...
www.cureus.comThrombotic microangiopathies (TMAs) include a heterogeneous group of diseases characterized by abnormalities in the vessel walls of arterioles and capillaries resulting in microvascular thrombosis that typically presents with a microangiopathic ...
pmc.ncbi.nlm.nih.govMicroangiopathic hemolytic anemia (MAHA) is a condition characterized by intravascular fragmentation of red blood cells, leading to the characteristic finding of schistocytes on a peripheral blood smear. The differential diagnoses of MAHA include thrombotic thrombocytopenic purpura (TTP), hemolytic- …
pubmed.ncbi.nlm.nih.govDiagnosis and treatment of acquired hemolytic anemia can be challenging. In this How I Treat series, edited by Mario Cazzola, clinical experts discuss thei
ashpublications.orgA process of red blood cell destruction within the microvasculature; seen in: Thrombotic microangiopathiesValve hemolysisFoot strike anemia Up-to-Date:
www.thebloodproject.comMicroangiopathic Hemolytic Anemia - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the Merck Manuals - Medical Professional Version.
www.merckmanuals.comFrequency of microangiopathic hemolytic anemia in patients with systemic lupus erythematosus exacerbation: Distinction from thrombotic thrombocytopenic purpura, prognosis, and outcome
www.academia.eduRed blood cells (RBCs) start to break down early in hemolytic anemia, which can be chronic or life-threatening. It should be considered while determining if normocytic or macrocytic anemia is present. Hemolysis in the reticuloendothelial system may ...
pmc.ncbi.nlm.nih.govMicroangiopathic Hemolytic Anemia - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the Merck Manuals - Medical Professional Version.
www.merckmanuals.com